Amanote Research
Register
Sign In
Orphan Medicines: The High Cost of Hope
Prescriber
- United Kingdom
doi 10.1002/psb.1640
Full Text
Open PDF
Abstract
Available in
full text
Categories
Pharmacology
Date
January 1, 2018
Authors
Sarah Houlton
Publisher
Wiley
Related search
Php109 - Cost of Unlicenced and Orphan Medicines in Turkey, Kazakhstan and Poland
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
Low Availability of Orphan Medicines in Serbia
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
Php162 - Licenced Orphan Medicines Expenditure in Turkey
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
Access to High Cost Medicines in Australia: Ethical Perspectives
Australia and New Zealand Health Policy
Erratum To: Establishing Medical Plausibility in the Context of Orphan Medicines Designation in the European Union
Orphanet Journal of Rare Diseases
Medicine
Genetics
Pharmacology
Hope for Fish on the High Seas
Nature Food
Safe and Sound: Applying Quality Use of Medicines to High‐risk Medicines
Journal of Pharmacy Practice and Research
Pharmacology
Pharmacy
Prescribing Errors by Junior Doctors- A Comparison of Errors With High Risk Medicines and Non-High Risk Medicines
PLoS ONE
Multidisciplinary
Prescribed Medicines Skipped Due to Cost, 2016 (Or Nearest Year)
Health at a Glance 2017